PT986393E - Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro - Google Patents

Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro

Info

Publication number
PT986393E
PT986393E PT98923772T PT98923772T PT986393E PT 986393 E PT986393 E PT 986393E PT 98923772 T PT98923772 T PT 98923772T PT 98923772 T PT98923772 T PT 98923772T PT 986393 E PT986393 E PT 986393E
Authority
PT
Portugal
Prior art keywords
cancer
nitroxide
therapeutic treatment
profilactic
pharmacy
Prior art date
Application number
PT98923772T
Other languages
English (en)
Inventor
Angelo Russo
James B Mitchell
Anne Marie Deluca
Murali Krishna Cherukuri
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of PT986393E publication Critical patent/PT986393E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT98923772T 1997-05-27 1998-05-27 Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro PT986393E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4772497P 1997-05-27 1997-05-27

Publications (1)

Publication Number Publication Date
PT986393E true PT986393E (pt) 2004-06-30

Family

ID=21950574

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98923772T PT986393E (pt) 1997-05-27 1998-05-27 Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro

Country Status (10)

Country Link
EP (1) EP0986393B1 (pt)
JP (3) JP4856294B2 (pt)
AT (1) ATE262330T1 (pt)
AU (1) AU746505B2 (pt)
CA (1) CA2289017C (pt)
DE (1) DE69822626T8 (pt)
DK (1) DK0986393T3 (pt)
ES (1) ES2216286T3 (pt)
PT (1) PT986393E (pt)
WO (1) WO1998053835A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096759A (en) * 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
CA2335986A1 (en) 1998-06-26 2000-01-06 Simeng Suy Use of tempo and tempo derivatives for inducing cell death
US20040219201A1 (en) * 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
JP2007500227A (ja) * 2003-05-29 2007-01-11 ミトス・ファーマシューティカルズ・インコーポレーテッド 光増感剤及び音増感剤と関連してのニトロキシドの使用方法
US20120046314A1 (en) * 2005-02-02 2012-02-23 Mitos, Inc. Nitroxides for use in treating or preventing neoplastic disease
US8466130B2 (en) 2009-09-04 2013-06-18 Colby Pharmaceutical Company Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
WO2008109740A2 (en) * 2007-03-06 2008-09-12 Colby Pharmaceutical Company Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
US8853277B2 (en) 2009-11-30 2014-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)
US20180078539A1 (en) 2016-03-23 2018-03-22 Louis Habash T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide
US10231959B2 (en) 2016-03-23 2019-03-19 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
WO2017165572A1 (en) * 2016-03-23 2017-09-28 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758580A (en) * 1985-06-26 1988-07-19 Yamanouchi Pharmaceutical Co., Ltd. Inhibiting growth of tumors with certain substituted phenoxy dimethyl alkanoic acids, esters or salts
EP0462305B1 (de) * 1990-06-21 1994-11-02 Huland, Edith, Dr. Dr. Verwendung zytokinhaltiger Aerosole und zytokinhaltige Aerosole selbst
US6605619B1 (en) * 1992-03-20 2003-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxides as protectors against oxidatives stress
CA2212370A1 (en) * 1995-02-16 1996-08-22 Moses Judah Folkman Inhibition of angiogenesis using interleukin-12

Also Published As

Publication number Publication date
EP0986393A1 (en) 2000-03-22
CA2289017C (en) 2008-07-22
AU7598798A (en) 1998-12-30
JP2013121964A (ja) 2013-06-20
DE69822626D1 (de) 2004-04-29
JP2002500671A (ja) 2002-01-08
AU746505B2 (en) 2002-05-02
DK0986393T3 (da) 2004-07-05
DE69822626T8 (de) 2005-02-03
CA2289017A1 (en) 1998-12-03
EP0986393B1 (en) 2004-03-24
JP2009185034A (ja) 2009-08-20
ES2216286T3 (es) 2004-10-16
JP5270413B2 (ja) 2013-08-21
ATE262330T1 (de) 2004-04-15
DE69822626T2 (de) 2004-08-12
WO1998053835A1 (en) 1998-12-03
JP4856294B2 (ja) 2012-01-18

Similar Documents

Publication Publication Date Title
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
ATE207355T1 (de) Behandlung von hyperproliferativen gefässerkrankungen
GB0005251D0 (en) Therapeutic compounds
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
BR9714677A (pt) "enantiÈmeros 3-piridila e seu uso como analgésicos"
UA41355C2 (uk) Засіб для лікування нейро-сніду
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
NO20000446D0 (no) Anvendelse av fysiologisk akseptable vanadiumforbindelser, salter og komplekser
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
EA200100716A1 (ru) Способ профилактики рака молочной железы
PT1039900E (pt) Agentes terapeuticos
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
NZ511559A (en) Use of staurosporine derivatives for treating ocular neovascular diseases
TR200103561T2 (tr) Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
ATE141506T1 (de) Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff
NO923198L (no) Terapeutiske midler
DE69633673D1 (de) Verwendung von Halofuginon zur Herstellung eines Medikaments zur Vorbeugung von Neovaskularisation und zur Behandlung bösartiger Tumore
DE50109320D1 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
BR9808305A (pt) Forma hidratada cristalina, processo para a preparação da forma hidratada cristalina, composição farmacêutica, processo de tratamento de um mamìfero, e, processo de tratamento ou de prevenção de dor.
EP2266566A3 (en) Nicotinamide derivatives and their use as therapeutic agents